Processa Pharmaceuticals IncPCSA
Price$1.62

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$13.6MTTM through 31 Dec 2025
Free Cash Flow -$11.4MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%

Returns

-243.0%ROE
-174.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.54x
Net Debt-$5.5Mnet cash position
Cash & Equivalents$5.5M

Quality Metrics

Earnings-Beat Rate75.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Next Generation Cancer therapies$00.0%
View details

Focusing on clinical development of NGC-Cap and NGC-Iri

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.